Managing Refractoriness: Modern Strategy for Refractory Celiac Disease
DOI:
https://doi.org/10.12775/QS.2026.49.67052Keywords
refractory celiac disease, celiac disease, enteropathy-associated T-cell lymphomaAbstract
Celiac disease (CD), also known as gluten-sensitive enteropathy, is the most common autoimmune disorder in today’s society. CD is associated with both human leukocyte antigen (HLA) and non-HLA genes. It often coexists with other autoimmune diseases, such as juvenile diabetes and thyroid disease. Diagnosis often relies on biopsy results, but serological tests are also very useful when screening patients suspected of having CD. Although our knowledge of celiac disease seems thorough, the pathogenesis of refractory celiac disease (RCD) is still under research. Treating RCD can be challenging, and it is crucial to provide care in experienced tertiary centers. Treatment may involve dietary and pharmacological approaches, depending on the type of RCD. This reduces the risk of disease progression and alleviates the symptoms. Investigations into other innovative treatment methods are ongoing.
References
1. Caio G, Volta U, Sapone A, et al. Celiac disease: a comprehensive current review. BMC Med. 2019;17(1):142. doi:10.1186/s12916-019-1380-z
2. Green PHR, Paski S, Ko CW, Rubio-Tapia A. AGA Clinical Practice Update on Management of Refractory Celiac Disease: Expert Review. Gastroenterology. 2022;163(5):1461-1469. doi:10.1053/j.gastro.2022.07.086
3. Parzanese I, Qehajaj D, Patrinicola F, et al. Celiac disease: From pathophysiology to treatment. World J Gastrointest Pathophysiol. 2017;8(2):27-38. doi:10.4291/wjgp.v8.i2.27
4. Malamut G, Soderquist CR, Bhagat G, Cerf-Bensussan N. Advances in Nonresponsive and Refractory Celiac Disease. Gastroenterology. 2024;167(1):132-147. doi:10.1053/j.gastro.2024.02.048
5. Penny HA, Rej A, Baggus EMR, et al. Non-Responsive and Refractory Coeliac Disease: Experience from the NHS England National Centre. Nutrients. 2022;14(13):2776. doi:10.3390/nu14132776
6. Woodward J. The management of refractory coeliac disease. Ther Adv Chronic Dis. 2013;4(2):77-90. doi:10.1177/2040622312473174
7. Verdelho Machado M. Refractory Celiac Disease: What the Gastroenterologist Should Know. Int J Mol Sci. 2024;25(19):10383. doi:10.3390/ijms251910383
8. Scarmozzino F, Pizzi M, Pelizzaro F, et al. Refractory celiac disease and its mimickers: a review on pathogenesis, clinical-pathological features and therapeutic challenges. Front Oncol. 2023;13:1273305. doi:10.3389/fonc.2023.1273305
9. Kagnoff MF. Overview and pathogenesis of celiac disease. Gastroenterology. 2005;128(4):S10-S18. doi:10.1053/j.gastro.2005.02.008
10. van de Wal Y, Kooy YMC, van Veelen P, et al. Glutenin is involved in the gluten-driven mucosal T cell response. Eur J Immunol. 1999;29(10):3133-3139. doi:10.1002/(SICI)1521-4141(199910)29:10%3C3133::AID-IMMU3133%3E3.0.CO;2-G
11. Wieser H. 1 The precipitating factor in coeliac disease. Baillières Clin Gastroenterol. 1995;9(2):191-207. doi:10.1016/0950-3528(95)90027-6
12. Malamut G, El Machhour R, Montcuquet N, et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease–associated inflammation and lymphomagenesis. J Clin Invest. 2010;120(6):2131-2143. doi:10.1172/JCI41344
13. Malamut G, Afchain P, Verkarre V, et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology. 2009;136(1):81-90. doi:10.1053/j.gastro.2008.09.069
14. Baggus EMR, Hadjivassiliou M, Cross S, et al. How to manage adult coeliac disease: perspective from the NHS England Rare Diseases Collaborative Network for Non-Responsive and Refractory Coeliac Disease. Frontline Gastroenterol. 2020;11(3):235-242. doi:10.1136/flgastro-2019-101191
15. Rubio-Tapia A, Murray JA. Classification and Management of Refractory Celiac Disease. Gut. 2010;59(4):547-557. doi:10.1136/gut.2009.195131
16. Rej A, Sanders DS. An update on coeliac disease from the NHS England National Centre for Refractory Coeliac Disease. Clin Med. 2021;21(2):127-130. doi:10.7861/clinmed.2021-0025
17. Chibbar R, Nostedt J, Mihalicz D, Deschenes J, McLean R, Dieleman LA. Refractory Celiac Disease Type II: A Case Report and Literature Review. Front Med. 2020;7:564875. doi:10.3389/fmed.2020.564875
18. Rubio-Tapia A, Kelly DG, Lahr BD, Dogan A, Wu TT, Murray JA. CLINICAL STAGING AND SURVIVAL IN REFRACTORY CELIAC DISEASE: A SINGLE CENTER EXPERIENCE. Gastroenterology. 2009;136(1):99-353. doi:10.1053/j.gastro.2008.10.013
19. Abdullah SAA, Goa P, Vandenberghe E, Flavin R. Update on the Pathogenesis of Enteropathy-Associated T-Cell Lymphoma. Diagnostics. 2023;13(16):2629. doi:10.3390/diagnostics13162629
20. Wang M, Yu M, Kong WJ, Cui M, Gao F. Association between intestinal neoplasms and celiac disease: A review. World J Gastrointest Oncol. 2021;13(9):1017-1028. doi:10.4251/wjgo.v13.i9.1017
21. Ludvigsson JF, Bai JC, Biagi F, et al. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut. 2014;63(8):1210-1228. doi:10.1136/gutjnl-2013-306578
22. Al-Toma A, Volta U, Auricchio R, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United Eur Gastroenterol J. 2019;7(5):583-613. doi:10.1177/2050640619844125
23. Elli L, Soru P, Roncoroni L, et al. Clinical features of type 1 and 2 refractory celiac disease: Results from a large cohort over a decade. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2023;55(2):235-242. doi:10.1016/j.dld.2022.08.022
24. Nasr I, Nasr I, Beyers C, Chang F, Donnelly S, Ciclitira PJ. Recognising and Managing Refractory Coeliac Disease: A Tertiary Centre Experience. Nutrients. 2015;7(12):9896-9907. doi:10.3390/nu7125506
25. Malamut G, Cording S, Cerf-Bensussan N. Recent advances in celiac disease and refractory celiac disease. F1000Research. 2019;8:F1000 Faculty Rev-969. doi:10.12688/f1000research.18701.1
26. Al-Bawardy B, Barlow JM, Vasconcelos RN, et al. Cross-sectional imaging in refractory celiac disease. Abdom Radiol N Y. 2017;42(2):389-395. doi:10.1007/s00261-016-1032-0
27. Zammit SC, Elli L, Scaramella L, Sanders DS, Tontini GE, Sidhu R. Small bowel capsule endoscopy in refractory celiac disease: a luxury or a necessity? Ann Gastroenterol. 2021;34(2):188-195. doi:10.20524/aog.2021.0586
28. Nasr I, Nasr I, Campling H, Ciclitira PJ. Approach to patients with refractory coeliac disease. F1000Research. 2016;5:F1000 Faculty Rev-2544. doi:10.12688/f1000research.9051.1
29. Nishimura MF, Nishimura Y, Nishikori A, Yoshino T, Sato Y. Primary Gastrointestinal T-Cell Lymphoma and Indolent Lymphoproliferative Disorders: Practical Diagnostic and Treatment Approaches. Cancers. 2021;13(22):5774. doi:10.3390/cancers13225774
30. Pelizzaro F, Marsilio I, Fassan M, et al. The Risk of Malignancies in Celiac Disease—A Literature Review. Cancers. 2021;13(21):5288. doi:10.3390/cancers13215288
31. Penny HA, Baggus EMR, Rej A, Snowden JA, Sanders DS. Non-Responsive Coeliac Disease: A Comprehensive Review from the NHS England National Centre for Refractory Coeliac Disease. Nutrients. 2020;12(1):216. doi:10.3390/nu12010216
32. Mukewar SS, Sharma A, Rubio-Tapia A, Wu TT, Jabri B, Murray JA. Open-Capsule Budesonide for Refractory Celiac Disease. Am J Gastroenterol. 2017;112(6):959-967. doi:10.1038/ajg.2017.71
33. Tack GJ, Verbeek WHM, Al-Toma A, et al. Evaluation of Cladribine treatment in refractory celiac disease type II. World J Gastroenterol. 2011;17(4):506-513. doi:10.3748/wjg.v17.i4.506
34. Al-toma A, Visser OJ, van Roessel HM, et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood. 2007;109(5):2243-2249. doi:10.1182/blood-2006-08-042820
35. Dieckman T, Schumann M, Beaumont H, et al. Enduring Clinical Remission in Refractory Celiac Disease Type II With Tofacitinib: An Open-Label Clinical Study. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2024;22(11):2334-2336. doi:10.1016/j.cgh.2024.05.022
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Roksana Grzeszczak, Aleksandra Fałczyńska, Aleksandra Balak, Weronika Szkudlarek, Katarzyna Rotte, Maksymilian Grabarczyk, Igor Piotrowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 28
Number of citations: 0
